Pfizer and RemeGen's HER2 antibody-drug conjugate delivered positive phase 3 results in a bladder cancer trial in China. | ...

The proposed 10% tariff, which mirrors India’s tax on US drug imports, could severely impact profit margins for generic drug ...

FY25 net profit beat expectations due to higher other income and a lower tax outgo, EBITDA came in slightly below estimates because of increased R&D expenditure.

Eicher Motors, Aditya Birla Real Estate, ADF Foods, Agi Greenpac, Ajmera Realty & Infra India, Akzo Nobel India, Apar ...

Cipla also allayed concerns that the US government's drug pricing executive order on pharma companies, aimed at lowering cost ...

Vohra stated that the directive appears to be primarily aimed at branded pharmaceutical products rather than generic ...

The pharmaceutical segment contributed Rs 6,503.63 crore to the quarterly revenue, reflecting an 8.5 per cent growth, while ...

Cipla CEO Umang Vohra discusses challenges in pharmaceutical industry, including US tariffs, with uncertain future ahead.

Cipla CEO Umang Vohra discusses US government's order on prescription drug prices, impact on generic drugmakers.

Cipla CEO says US order to lower drug prices won't impact Indian generic drugmakers. The order is likely to target branded ...

Cipla reported a 30% increase in net profit, reaching Rs 1,222 crore in Q4 FY25, fueled by higher sales in India, the US, and ...

Cipla has reported 30.1% increase in consolidated net profit to Rs 1,222 crore on a 9.2% rise in total income to Rs 6,730 crore in Q4 FY25 as compared with Q4 FY24.